Aptose Biosciences (NASDAQ:APTO) Lowered to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a buy rating to a hold rating in a research note published on Monday morning, Zacks.com reports.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

APTO has been the topic of several other reports. Roth Capital reiterated a buy rating on shares of Aptose Biosciences in a report on Thursday, May 23rd. HC Wainwright dropped their target price on Aptose Biosciences from $8.50 to $6.00 and set a buy rating on the stock in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $5.25.

NASDAQ APTO opened at $2.38 on Monday. The company has a quick ratio of 11.27, a current ratio of 11.27 and a debt-to-equity ratio of 0.04. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $3.20. The business’s 50-day simple moving average is $2.65 and its 200-day simple moving average is $2.16.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, equities research analysts predict that Aptose Biosciences will post -0.59 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new stake in shares of Aptose Biosciences during the 4th quarter valued at about $33,000. Boston Advisors LLC purchased a new stake in Aptose Biosciences during the 1st quarter worth approximately $36,000. Gagnon Securities LLC purchased a new stake in Aptose Biosciences during the 2nd quarter worth approximately $146,000. Patriot Financial Group Insurance Agency LLC increased its holdings in Aptose Biosciences by 37.3% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 21,400 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Aptose Biosciences during the 1st quarter worth approximately $198,000. Institutional investors and hedge funds own 6.74% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More: Stop Order

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Advanced Micro Devices, Inc.  CAO Sells $281,249.64 in Stock
Insider Selling: Advanced Micro Devices, Inc. CAO Sells $281,249.64 in Stock
Jack in the Box Inc.  CEO Sells $267,000.00 in Stock
Jack in the Box Inc. CEO Sells $267,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock   Insider Buys C$270,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock Insider Buys C$270,000.00 in Stock
Blucora  Downgraded to “Sell” at Zacks Investment Research
Blucora Downgraded to “Sell” at Zacks Investment Research
Assembly Biosciences  Cut to Hold at Zacks Investment Research
Assembly Biosciences Cut to Hold at Zacks Investment Research
Aptose Biosciences  Lowered to Hold at Zacks Investment Research
Aptose Biosciences Lowered to Hold at Zacks Investment Research


© 2006-2019 Ticker Report